Tirzepatide Research for Type 2 Diabetes
An evidence-based overview of research examining Tirzepatide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tirzepatide was first FDA-approved for type 2 diabetes in 2022 (as Mounjaro). The SURPASS program demonstrated HbA1c reductions of 2.0-2.3% at the highest doses, exceeding semaglutide in head-to-head comparisons. The dual GIP/GLP-1 mechanism harnesses the full incretin effect, as GIP accounts for 60-65% of the natural postprandial insulin response. SURPASS-2 showed tirzepatide superior to semaglutide for both HbA1c reduction and weight loss. The SURPASS-CVOT trial has confirmed cardiovascular safety with non-inferiority to dulaglutide for major adverse cardiovascular events (MACE).
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tirzepatide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.